Jeffrey W. Kalenak

TL;DR: A gene encoding a trabecular meshwork protein (TIGR) mapped to the narrowest disease interval by STS content and radiation hybrid mapping and will aid in early diagnosis of glaucoma.

TL;DR: Both implants were effective in reducing IOP and the need for glaucoma medications and the Baerveldt group had a lower failure rate and a lower IOP on fewer medications than the Ahmed group, but had a small risk of hypotony that was not seen in the Ahmed Group.

TL;DR: The Ahmed Versus Baerveldt (AVB) study as discussed by the authors reported the 1-year treatment outcomes of the AVB study, where patients with uncontrolled glaucoma refractory to medicinal, laser, and surgical therapy were randomized to undergo implantation of an Ahmed-FP7 valve (New World Medical, Inc., Rancho Cucamonga, CA) or a Baervesldt-350 implant (Abbott Medical Optics, Inc, Santa Ana, CA), to be followed for 5 years.

TL;DR: Autosomal dominant iris hypoplasia is caused by a defect in the same gene that is defective in many cases of Rieger syndrome, the RIEG/PITX2 gene product.

TL;DR: Aqueous shunt procedures may be associated with significant retinal complications and subsequent visual loss and experience with the Ahmed glaucoma valve implant.